Pacira BioSciences, Inc. Cash Flow Statement
PCRX / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Pacira BioSciences, Inc. generated $152M in operating cash flow and $137M in free cash flow in FY2025. Free cash flow margin was 18.8% of revenue.
Based on SEC 10-K filings.
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Negative profit margin: -14.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $7.0M | -$99.6M | $42.0M | $15.9M | -$11.0M | -$471.0K | -$42.6M | -$37.9M | $1.9M | -$37.9M | $1.9M | -$13.7M | -$43.3M | -$27.1M | -$43.3M |
| Depreciation & Amortization | $91.0M | $78.8M | $75.6M | $91.5M | $19.6M | $13.2M | $13.8M | $12.9M | $11.5M | $12.9M | $11.5M | $10.0M | $4.3M | $4.1M | $4.3M |
| Operating Cash Flow | $152.0M | $189.4M | $154.6M | $145.3M | $70.5M | $48.9M | $17.8M | $33.5M | $28.0M | $33.5M | $28.0M | $26.6M | -$31.0M | -$24.9M | -$31.0M |
| Capital Expenditures | $15.3M | $10.6M | $15.2M | $30.1M | $10.2M | $14.5M | $19.3M | $24.7M | $40.3M | $24.7M | $40.3M | $23.0M | $6.2M | $6.8M | $6.2M |
| Free Cash Flow | $136.7M | $178.8M | $139.5M | $115.2M | $60.4M | $34.4M | -$1.5M | $8.7M | -$12.3M | $8.7M | -$12.3M | $3.6M | -$37.2M | -$31.6M | -$37.2M |
| Share Buybacks | $148.3M | $25.0M | $0 | $0 | - | - | - | - | - | - | - | - | - | $2.0K | - |
| FCF Margin | 18.8% | 25.5% | 20.7% | 17.3% | 14.3% | 10.2% | -0.5% | 3.2% | -4.9% | 3.2% | -4.9% | 1.8% | -236.9% | -217.4% | -236.9% |